Cryo-Cell International (CCEL) vs Fresenius Medical Care (FMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cryo-Cell International (CCEL) has outperformed Fresenius Medical Care (FMS) over the past year, losing 11.3% versus a loss of 22.9%. Over five years, FMS leads with a -41.7% price change compared with -70.3% for CCEL. Fresenius Medical Care is the larger company by market cap ($11.01 billion vs $31.5 million), about 349.3 times the size.
On valuation, Fresenius Medical Care trades at a lower forward P/E (6.9x vs 195.5x for Cryo-Cell International). Fresenius Medical Care pays a dividend yielding 7.20%, while Cryo-Cell International does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCEL | FMS |
|---|---|---|
| Share price | $3.91 | $20.69 |
| Market cap | $31.52M | $11.01B |
| 1-day change | +0.77% | -7.72% |
| YTD return | +13.66% | -13.14% |
| 1-year return | -11.34% | -22.86% |
| 5-year return | -70.27% | -41.65% |
| P/E ratio (TTM) | — | 10.66 |
| Forward P/E | 195.50 | 6.92 |
| EPS (TTM) | $-0.31 | $1.94 |
| Dividend yield | 0.00% | 7.20% |
| Annual dividend | $0.00 | $1.49 |
| Revenue (latest FY) | — | $4.97B |
| Revenue growth (YoY) | — | -63.98% |
| Net income (latest FY) | — | $1.11B |
| Gross margin | — | 95.33% |
| Operating margin | — | 45.39% |
| Net margin | — | 22.33% |
| 52-week high | $4.90 | $27.64 |
| 52-week low | $2.72 | $20.02 |
| Distance from 52-week high | -20.20% | -25.14% |
| Analyst consensus | — | hold |
| Avg. price target upside | — | +13.24% |
| Average volume | 23.32K | 740.08K |
| Shares outstanding | 8.06M | 532.22M |
| Employees | — | 107,226 |
| Sector | Health Care | Health Care |
| Industry | Misc Health and Biotechnology Services | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Fresenius Medical Care is about 349.3 times larger than Cryo-Cell International by market value ($11.01B vs $31.52M).
- CCEL has outperformed FMS by 11.5 percentage points over the past year.
- Fresenius Medical Care offers a meaningfully higher dividend yield (7.20% vs 0.00%).
About Fresenius Medical Care
FMS stock →Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Health Care · Misc Health and Biotechnology Services · 107,226 employees
CCEL vs FMS FAQ
Which is bigger, Cryo-Cell International or Fresenius Medical Care?
Fresenius Medical Care (FMS) is larger, with a market capitalization of $11.01B compared with $31.52M for Cryo-Cell International (CCEL).
Which stock has performed better over the past year, CCEL or FMS?
CCEL returned -11.34% over the past 12 months, compared with -22.86% for FMS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Cryo-Cell International or Fresenius Medical Care?
Fresenius Medical Care pays a dividend yielding 7.20%, while Cryo-Cell International does not currently pay a regular dividend.
Are Cryo-Cell International and Fresenius Medical Care in the same industry?
Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.